The Amgen/Novartis story. A little curiosity about Alder Biopharmaceuticals.

In May 2018 Novartis (NVS) and Amgen (AMGN) announced that their novel migraine drug Aimovig™ was been granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically block calcitonin-gene-related peptide receptor (CGRP-R) believed to play a critical role in causing migraines. 
In the press release that announced the approval of Aimovig both Novartis and Amgen expressed their excitement; observing the novel drug reaches the migraine sufferers.

This content is for paid subscribers.
Please click here to subscribe or here to log in.